253 related articles for article (PubMed ID: 24591487)
1. The lumped constant for the galactose analog 2-18F-fluoro-2-deoxy-D-galactose is increased in patients with parenchymal liver disease.
Mikkelsen KS; Sørensen M; Frisch K; Villadsen GE; Bibby BM; Keiding S
J Nucl Med; 2014 Apr; 55(4):590-4. PubMed ID: 24591487
[TBL] [Abstract][Full Text] [Related]
2. Hepatic galactose metabolism quantified in humans using 2-18F-fluoro-2-deoxy-D-galactose PET/CT.
Sørensen M; Mikkelsen KS; Frisch K; Bass L; Bibby BM; Keiding S
J Nucl Med; 2011 Oct; 52(10):1566-72. PubMed ID: 21875925
[TBL] [Abstract][Full Text] [Related]
3. Regional metabolic liver function measured in patients with cirrhosis by 2-[¹⁸F]fluoro-2-deoxy-D-galactose PET/CT.
Sørensen M; Mikkelsen KS; Frisch K; Villadsen GE; Keiding S
J Hepatol; 2013 Jun; 58(6):1119-24. PubMed ID: 23339954
[TBL] [Abstract][Full Text] [Related]
4. Hepatic uptake and metabolism of galactose can be quantified in vivo by 2-[18F]fluoro-2-deoxygalactose positron emission tomography.
Sørensen M; Munk OL; Mortensen FV; Olsen AK; Bender D; Bass L; Keiding S
Am J Physiol Gastrointest Liver Physiol; 2008 Jul; 295(1):G27-G36. PubMed ID: 18483186
[TBL] [Abstract][Full Text] [Related]
5. Determination of hepatic galactose elimination capacity using 2-[¹⁸F]fluoro-2-deoxy-D-galactose PET/CT: reproducibility of the method and metabolic heterogeneity in a normal pig liver model.
Sørensen M
Scand J Gastroenterol; 2011 Jan; 46(1):98-103. PubMed ID: 20695723
[TBL] [Abstract][Full Text] [Related]
6. Methodologic Considerations for Quantitative 18F-FDG PET/CT Studies of Hepatic Glucose Metabolism in Healthy Subjects.
Trägårdh M; Møller N; Sørensen M
J Nucl Med; 2015 Sep; 56(9):1366-71. PubMed ID: 26159590
[TBL] [Abstract][Full Text] [Related]
7. 2-[(18)F]fluoro-2-deoxy-D-galactose PET/CT of hepatocellular carcinoma is not improved by co-administration of galactose.
Bak-Fredslund KP; Munk OL; Keiding S; Sørensen M
Nucl Med Biol; 2016 Sep; 43(9):577-580. PubMed ID: 27434609
[TBL] [Abstract][Full Text] [Related]
8. Metabolic liver function in humans measured by 2-
Bak-Fredslund KP; Lykke Eriksen P; Munk OL; Villadsen GE; Keiding S; Sørensen M
EJNMMI Res; 2017 Aug; 7(1):71. PubMed ID: 28853060
[TBL] [Abstract][Full Text] [Related]
9. Accumulation of 2-deoxy-2-[18F]fluoro-D-galactose in the liver by phosphate and uridylate trapping.
Ishiwata K; Ido T; Imahori Y; Yamaguchi K; Fukuda H; Tada M; Matsuzawa T
Int J Rad Appl Instrum B; 1988; 15(3):271-6. PubMed ID: 3260229
[TBL] [Abstract][Full Text] [Related]
10. Hepatic blood perfusion measured by 3-minute dynamic 18F-FDG PET in pigs.
Winterdahl M; Munk OL; Sørensen M; Mortensen FV; Keiding S
J Nucl Med; 2011 Jul; 52(7):1119-24. PubMed ID: 21680685
[TBL] [Abstract][Full Text] [Related]
11. Metabolic liver function measured in vivo by dynamic (18)F-FDGal PET/CT without arterial blood sampling.
Horsager J; Munk OL; Sørensen M
EJNMMI Res; 2015; 5():32. PubMed ID: 26034654
[TBL] [Abstract][Full Text] [Related]
12. Nucleophilic radiosynthesis of 2-[18F]fluoro-2-deoxy-D-galactose from Talose triflate and biodistribution in a porcine model.
Frisch K; Bender D; Hansen SB; Keiding S; Sørensen M
Nucl Med Biol; 2011 May; 38(4):477-83. PubMed ID: 21531284
[TBL] [Abstract][Full Text] [Related]
13. [
Bak-Fredslund KP; Keiding S; Villadsen GE; Kramer S; Schlander S; Sørensen M
Liver Int; 2020 Feb; 40(2):447-455. PubMed ID: 31705784
[TBL] [Abstract][Full Text] [Related]
14. Effect of stereotactic body radiotherapy on regional metabolic liver function investigated in patients by dynamic [
Sørensen M; Fode MM; Petersen JB; Holt MI; Høyer M
Radiat Oncol; 2021 Oct; 16(1):192. PubMed ID: 34598730
[TBL] [Abstract][Full Text] [Related]
15. The potential use of 2-[¹⁸F]fluoro-2-deoxy-D-galactose as a PET/CT tracer for detection of hepatocellular carcinoma.
Sørensen M; Frisch K; Bender D; Keiding S
Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1723-31. PubMed ID: 21553087
[TBL] [Abstract][Full Text] [Related]
16. A phase I study on stereotactic body radiotherapy of liver metastases based on functional treatment planning using positron emission tomography with 2-[
Fode MM; Bak-Fredslund K; Petersen JB; Worm E; Sørensen M; Høyer M
Acta Oncol; 2017 Nov; 56(11):1614-1620. PubMed ID: 28849688
[TBL] [Abstract][Full Text] [Related]
17. Liver kinetics of glucose analogs measured in pigs by PET: importance of dual-input blood sampling.
Munk OL; Bass L; Roelsgaard K; Bender D; Hansen SB; Keiding S
J Nucl Med; 2001 May; 42(5):795-801. PubMed ID: 11337579
[TBL] [Abstract][Full Text] [Related]
18. In vivo assessment of 6-deoxy-6-[18F]fluoro-D-galactose as a PET tracer for studying galactose metabolism.
Ishiwata K; Tomura M; Ido T; Iwata R; Itoh J; Kameyama M
Int J Rad Appl Instrum B; 1989; 16(8):775-81. PubMed ID: 2621112
[TBL] [Abstract][Full Text] [Related]
19. 2-Deoxy-2-[18F]fluoro-D-galactose as an in vivo tracer for imaging galactose metabolism in tumors with positron emission tomography.
Ishiwata K; Yamaguchi K; Kameyama M; Fukuda H; Tada M; Matsuzawa T; Muraishi K; Itoh J; Kawashima K; Takahashi T
Int J Rad Appl Instrum B; 1989; 16(3):247-54. PubMed ID: 2785512
[TBL] [Abstract][Full Text] [Related]
20. Quantification of liver glucose metabolism by positron emission tomography: validation study in pigs.
Iozzo P; Jarvisalo MJ; Kiss J; Borra R; Naum GA; Viljanen A; Viljanen T; Gastaldelli A; Buzzigoli E; Guiducci L; Barsotti E; Savunen T; Knuuti J; Haaparanta-Solin M; Ferrannini E; Nuutila P
Gastroenterology; 2007 Feb; 132(2):531-42. PubMed ID: 17258736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
